Press Releases
July 25, 2008
 | Jan Gray, CA Appointed to Board |
July 18, 2008
| RVX Highlighted in Well Regarded Journal |
July 09, 2008
| RVX-208 Among Top 10 Most Promising CVD Drugs |
June 19, 2008
| Collaboration with Cleveland Clinic |
June 18, 2008
| Exploratory Efficacy Analysis |
May 01, 2008
| Webcast & Update May 8 |
April 22, 2008
| Phase 1a Update |
April 21, 2008
| Share Options Extended |
January 14, 2008
| RVX-208's Early Success in Phase 1a |
December 10, 2007
| Phase 1 Clinical Trial Starts for RVX-208 |
November 29, 2007
| RVX only Canadian company to win World Economic Forum award |
November 05, 2007
| Dr. Jacques Genest Presents RVX-208 Data at the American Heart Association Conference |
October 12, 2007
| RVX Presenting at IAS in Santorini, Greece |
October 04, 2007
| Resverlogix Presents Data at DALM Scientific Conference |
September 17, 2007
| Stella Thomson Joins RVX Board of Directors |
September 12, 2007
| RVX Data Published in Current Opinion in Investigational Drugs |
September 10, 2007
| TGF-Beta Shield Potential New Therapy for Glaucoma |
September 04, 2007
| Amended Finance - Interest Rate Reduction |
August 27, 2007
| Interest Rate Increase |
August 14, 2007
| RVX Wins Frost & Sullivan's Excellence in Technology Award |
August 13, 2007
| Interest Rate Increase |
July 31, 2007
| RVX To Host Live Teleconference |
July 25, 2007
| Additional Proof-of-Concept in Non-Human Primates |
July 20, 2007
| RVX to Present Data at DALM Conference |
July 12, 2007
| Dr. Roger Newton speaks of Resverlogix |
June 08, 2007
| US $25M Bought Deal Closed |
June 06, 2007
| RVX to Close US $25M Bought Deal on June 7, 2007 |
June 05, 2007
| Resverlogix Closes US $25M Bought Deal |
April 25, 2007
| 28 & 42 Day Monkey Data |
April 09, 2007
| Webcast/Teleconference Corporate Update |
April 02, 2007
| ApoA-I White Paper |
April 02, 2007
| ACC Meeting Highlights Need for ApoA-I |
March 26, 2007
| Clinical Advisory Board Endorses RVX-208 |
March 20, 2007
| IND & Microdosing Update |
March 07, 2007
| RVX-208 Passes Key Toxicology Milestone |
March 05, 2007
| Alzheimer's Research Commences |
January 30, 2007
| Drs. Radar and Genest Join RVX Clinical Review Committee |
January 25, 2007
| RVX Hires Advisor for Strategic Alternatives |
January 05, 2007
| RVX Secures 17M Financing |
January 02, 2007
| Convertible Debt Financing |
December 20, 2006
| Drs. Barter and Shah Join CRC |
December 05, 2006
| RVX208 is positioned as a leader in ApoA-I/HDL Marketplace |
November 29, 2006
| Lead compound RVX-208 Increases ApoA-I By 150% |
November 14, 2006
| Expert Panel Reviews ApoA-I Enhancing Technologies |
September 28, 2006
| Resverlogix Corp. First Lead RVX-208 Raises ApoA-I up to 180% |
September 11, 2006
| Resverlogix Corp. Annouces First Man Trial |
August 23, 2006
| Resverlogix Corp. Granted Foreign Private Issuer Status |
August 14, 2006
| Resverlogix Corp. Expands CVD Franchise |
August 11, 2006
| ResVerlogix Announces Normal Course Issuer Bid |
July 24, 2006
| Resverlogix Corp. Announces Live Webcast Update |
April 28, 2006
| Resverlogix Corp. NexVas™ Education Program Wins Prestigious International Telly Award |
April 25, 2006
| Resverlogix moves closer to IND with the addition of Dr. Gregory S. Wagner as Vice President Preclinical Development |
February 23, 2006
| Resverlogix Corp. ReVas™ Licensing Update |
February 22, 2006
| Resverlogix Announces Live Web Cast Update |
